The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
In the latest session, Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) closed at $13.21 down -7.56% from its previous closing price of $14.29. In other words, the price has decreased by -$7.56 from its previous closing price. On the day, 0.57 million shares were traded.
Ratios:
For a deeper understanding of Arcturus Therapeutics Holdings Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.67 and its Current Ratio is at 4.67. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.10.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BTIG Research on January 28, 2025, initiated with a Buy rating and assigned the stock a target price of $41.
On August 12, 2024, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $70.
On December 13, 2023, Canaccord Genuity started tracking the stock assigning a Buy rating and target price of $90.Canaccord Genuity initiated its Buy rating on December 13, 2023, with a $90 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 15 ’24 when Chivukula Pad sold 12,000 shares for $20.76 per share. The transaction valued at 249,121 led to the insider holds 435,334 shares of the business.
Chivukula Pad bought 12,000 shares of ARCT for $249,121 on Oct 15 ’24. On Jun 12 ’24, another insider, SASSINE ANDY, who serves as the Chief Financial Officer of the company, sold 50,000 shares for $32.03 each. As a result, the insider received 1,601,500 and left with 220,526 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 2.59 while its Price-to-Book (P/B) ratio in mrq is 1.48.
Stock Price History:
Over the past 52 weeks, ARCT has reached a high of $45.00, while it has fallen to a 52-week low of $13.58. The 50-Day Moving Average of the stock is -21.23%, while the 200-Day Moving Average is calculated to be -36.87%.
Shares Statistics:
A total of 27.00M shares are outstanding, with a floating share count of 24.37M. Insiders hold about 10.14% of the company’s shares, while institutions hold 89.75% stake in the company.
Earnings Estimates
The market rating of Arcturus Therapeutics Holdings Inc (ARCT) is currently shaped by the ongoing analysis conducted by 8.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$1.05, with high estimates of -$0.37 and low estimates of -$2.16.
Analysts are recommending an EPS of between -$0.26 and -$8.79 for the fiscal current year, implying an average EPS of -$3.77. EPS for the following year is -$2.4, with 8.0 analysts recommending between $4.43 and -$5.77.
Revenue Estimates
Based on 10 analysts’ estimates, the company’s revenue will be $184.4M in the next fiscal year. The high estimate is $419.6M and the low estimate is $29.52M.
